Tirofiban Adjunct Therapy Improves Outcomes in Patients with Inadequate Tenecteplase Response
Trial shows tirofiban improves outcomes for some stroke patients
Intravenous tirofiban significantly improves 90-day functional outcomes for acute ischemic stroke patients failing initial tenecteplase ther…
A new clinical trial suggests that adding tirofiban can improve recovery rates for certain types of stroke patients who do not respond well …
Tenecteplase before EVT shows no functional benefit over EVT alone in late window stroke
Tenecteplase before clot removal did not improve stroke outcomes in this trial
A phase 3 trial found that intravenous tenecteplase before endovascular therapy did not improve functional independence at 90 days compared …
A large trial found giving tenecteplase before clot removal did not improve stroke recovery or safety compared to clot removal alone.
Intracranial hemorrhage rates were higher in tenecteplase than standard care at 14.4% versus 9.2% in minor ischemic stroke
Even small bleeds after minor stroke raise death risk in this trial analysis
This secondary analysis of a multicenter randomized controlled trial evaluated 865 patients with minor ischemic stroke within 12 hours of sy…
A look at trial data shows that small bleeds after minor stroke are linked to higher death rates, even if they do not worsen long-term funct…
Network meta-analysis compares alteplase, tenecteplase, and JX10 for acute ischemic stroke treatment outcomes
New analysis compares three clot-busting drugs for stroke patients treated up to twenty-four hours after symptoms start
This network meta-analysis evaluated intravenous thrombolytic agents for acute ischemic stroke. Alteplase significantly improved functional …
A large review found one standard drug helped more patients walk again than usual care, while a new drug showed promise but needs more testi…
IV tenecteplase beyond 4.5 hours shows modest benefit but higher bleeding risk in acute ischemic stroke patients
Tenecteplase shows modest benefit for late stroke treatment
A meta-analysis of 4000 adults treated with IV tenecteplase beyond 4.5 hours or for wake-up strokes found modest gains in functional recover…
A review of 4,000 adults found tenecteplase slightly improved recovery after stroke, but also raised bleeding risk, guiding careful use in s…
Tenecteplase linked to higher thrombus migration than alteplase in acute ischemic stroke with EVT
Tenecteplase linked to more clot movement than alteplase in stroke patients
This secondary analysis of a randomized controlled trial in 496 patients with intracranial occlusion found that IV tenecteplase was associat…
A study found tenecteplase caused more clot movement than alteplase in stroke patients. This movement was tied to better recovery odds.
Systematic review and meta-analysis of intra-arterial tenecteplase after endovascular thrombectomy for acute ischemic stroke
A Stroke Drug Given After Clot Removal Boosts Recovery
This systematic review and meta-analysis evaluated intra-arterial tenecteplase (IA-TNK) versus endovascular thrombectomy (EVT) alone in pati…
A clot-busting drug given right after a stroke procedure helped more patients walk and live independently, with no extra bleeding risk.
Rescue PCI after failed fibrinolysis linked to worse outcomes in STEMI compared to scheduled angiography
Rescue PCI after failed clot-busting drugs caused worse heart outcomes than planned angiography
This pre-specified analysis of the STREAM-2 RCT compared rescue PCI after failed fibrinolysis with scheduled angiography in 583 patients wit…
Patients needing emergency heart catheterization after clot-busting drugs fared worse than those who received planned procedures, with highe…
Tenecteplase shows worse functional outcomes in older patients with minor ischemic stroke compared to standard care
The Clot-Busting Drug That Backfires in Patients Over 80
This post hoc analysis of a randomized controlled trial evaluated tenecteplase versus nonthrombolytic standard of care in 884 patients with …
In patients over 80 with minor stroke, a clot-busting drug improved short-term recovery but worsened outcomes at 90 days compared to standar…
Cortical Superficial Siderosis Burden Predicts Hemorrhage and Poor Outcomes After Stroke Thrombolysis
New Brain Scan Marker Predicts Bleeding Risk Before Treatment
A substudy of the AcT trial (alteplase versus tenecteplase) evaluated radiological Boston CAA criteria and constituent markers in 482 thromb…
A specific brain scan pattern predicts dangerous bleeding after clot-busting drugs, helping doctors decide who needs fast treatment to save …
Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke
Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window
This randomized, open-label, blinded end-point trial evaluated intravenous tenecteplase versus standard medical treatment in 570 patients wi…
Tenecteplase helps late-arriving stroke patients recover better but raises bleeding risk, giving doctors a new tool for those beyond the usu…
Reteplase and non-immunogenic staphylokinase show superior functional outcomes vs alteplase in AIS within 4.5h
Which clot-busting drug works best for stroke? Two newer options may help more people walk and talk normally again
A network meta-analysis of 21 RCTs (n=16,837) found reteplase (18+18 mg) and non-immunogenic recombinant staphylokinase (10 mg) were associa…
Two newer clot-busting drugs help more stroke patients walk and talk normally again without increasing the risk of dying within 90 days.